BIOMAT Database Logo BIOMAT Database Logo

Use of nonnucleoside reverse-transcriptase inhibitors. 1998

C D Holtzer, and R L Coleman
UCSF AIDS Program, San Francisco General Hospital, CA 94110, USA. choltzer@sfaids.ucsf.edu

UI MeSH Term Description Entries
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D019829 Nevirapine A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. BI-RG-587,Nevirapine Hemihydrate,Viramune,BI RG 587,BIRG587,Hemihydrate, Nevirapine
D020008 Delavirdine A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Delavirdine Mesylate,Rescriptor,U-90152,U-90152S,Mesylate, Delavirdine,U 90152,U 90152S,U90152,U90152S

Related Publications

C D Holtzer, and R L Coleman
Nonnucleoside reverse transcriptase inhibitors.
October 1997, AIDS clinical care,
C D Holtzer, and R L Coleman
New nonnucleoside reverse transcriptase inhibitors.
February 1999, GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies,
C D Holtzer, and R L Coleman
Future of nonnucleoside reverse transcriptase inhibitors.
January 2018, Proceedings of the National Academy of Sciences of the United States of America,
C D Holtzer, and R L Coleman
Development of nonnucleoside HIV reverse transcriptase inhibitors.
January 1996, Methods in enzymology,
C D Holtzer, and R L Coleman
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
C D Holtzer, and R L Coleman
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
April 2002, Journal of acquired immune deficiency syndromes (1999),
C D Holtzer, and R L Coleman
Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
March 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
C D Holtzer, and R L Coleman
The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
January 2013, Advances in pharmacology (San Diego, Calif.),
C D Holtzer, and R L Coleman
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
November 2009, Journal of acquired immune deficiency syndromes (1999),
C D Holtzer, and R L Coleman
Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.
June 2001, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!